Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01786460 · ClinicalTrials.gov registry record

Brain Injury Biomarkers in the General Population

A clinical trial of Brain Injuries, Traumatic, sponsored by Banyan Biomarkers.

Completed
Registry status
800
Enrollment target
5
Study locations

NCT01786460 is a study of Brain Injuries, Traumatic that has completed, run by Banyan Biomarkers. The registered enrollment target is 800 participants, above the 218-participant average among 21 other Brain Injuries, Traumatic trials with a reported enrollment target (267% higher). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01786460, a study of Brain Injuries, Traumatic, has completed, sponsored by Banyan Biomarkers.

COMPLETED
Registry status
800 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to use an investigational assay to assess levels of putative biomarkers of traumatic brain injury (TBI) in a general population. The data will be used in a correlative analysis with data collected under a separate study of severe TBI.

Conditions Studied

Interventions

  • OTHER Blood draw at Days 0, 7, 14, and 21

Study Locations (5)

Georgia

  • Dekalb Medical Center - Decatur
  • Gwinnett Medical Center - Lawrenceville

California

  • Office of Nagi S. Ibrahim - Vista

Florida

  • Shands at University Florida Gainesville - Gainesville

Massachusetts

  • New England Center for Clinical Research - Fall River

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2011-01
Est. Completion 2011-09

Sponsor

Banyan Biomarkers

8 total trials

What the Registry Record Tells You About NCT01786460

The ClinicalTrials.gov registry entry for NCT01786460 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 21 other Brain Injuries, Traumatic trials with a reported enrollment target (267% higher). The listed sponsor is Banyan Biomarkers, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain Injuries, Traumatic appearing as the primary indexed condition, and to 1 intervention - of which Blood draw at Days 0, 7, 14, and 21 is the first listed.

NCT01786460 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Georgia, California, Florida.

Frequently Asked Questions

What is clinical trial NCT01786460 about?

NCT01786460 is a clinical study titled "Brain Injury Biomarkers in the General Population". The purpose of this study is to use an investigational assay to assess levels of putative biomarkers of traumatic brain injury (TBI) in a general population. The data will be used in a correlative analysis with data collected under a separate study of severe TBI.

What is the current status of trial NCT01786460?

This trial is currently completed. The enrollment target is 800 participants. The study started on 2011-01. Estimated completion is 2011-09.

What conditions does trial NCT01786460 study?

This clinical trial studies the following conditions: Brain Injuries, Traumatic.

What interventions are being tested in trial NCT01786460?

The interventions under investigation include: Blood draw at Days 0, 7, 14, and 21 (OTHER).

Who is sponsoring clinical trial NCT01786460?

This trial is sponsored by Banyan Biomarkers, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01786460 being conducted?

This trial has 5 study locations across California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain Injuries, Traumatic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.